Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
Status:
Withdrawn
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Secukinumab targets a different interleukin and has potential to be used as alternative to
existing treatments. This study will provide clinical data with respect to efficacy through
Psoriasis Area and Severity Index (PASI) at 16 weeks, safety/tolerability of secukinumab and
evaluate the impact of the treatment on quality of life and work productivity in subjects
with moderate to severe plaque psoriasis in the Turkish population.